HER2-Negative Breast Cancer Recruiting Phase 2 Trials for Epirubicin (DB00445)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02315196Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerTreatment